Form 8-K

8-K — Verastem, Inc.

Accession: 0001104659-26-057126

Filed: 2026-05-07

Period: 2026-05-07

CIK: 0001526119

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2613842d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2613842d1_ex99-1.htm)

GRAPHIC (tm2613842d1_ex99-1img001.jpg)

GRAPHIC (tm2613842d1_ex99-1img002.jpg)

GRAPHIC (tm2613842d1_ex99-1img003.jpg)

GRAPHIC (tm2613842d1_ex99-1img004.jpg)

GRAPHIC (tm2613842d1_ex99-1img005.jpg)

GRAPHIC (tm2613842d1_ex99-1img006.jpg)

GRAPHIC (tm2613842d1_ex99-1img007.jpg)

GRAPHIC (tm2613842d1_ex99-1img008.jpg)

GRAPHIC (tm2613842d1_ex99-1img009.jpg)

GRAPHIC (tm2613842d1_ex99-1img010.jpg)

GRAPHIC (tm2613842d1_ex99-1img011.jpg)

GRAPHIC (tm2613842d1_ex99-1img012.jpg)

GRAPHIC (tm2613842d1_ex99-1img013.jpg)

GRAPHIC (tm2613842d1_ex99-1img014.jpg)

GRAPHIC (tm2613842d1_ex99-1img015.jpg)

GRAPHIC (tm2613842d1_ex99-1img016.jpg)

GRAPHIC (tm2613842d1_ex99-1img017.jpg)

GRAPHIC (tm2613842d1_ex99-1img018.jpg)

GRAPHIC (tm2613842d1_ex99-1img019.jpg)

GRAPHIC (tm2613842d1_ex99-1img020.jpg)

GRAPHIC (tm2613842d1_ex99-1img021.jpg)

GRAPHIC (tm2613842d1_ex99-1img022.jpg)

GRAPHIC (tm2613842d1_ex99-1img023.jpg)

GRAPHIC (tm2613842d1_ex99-1img024.jpg)

GRAPHIC (tm2613842d1_ex99-1img025.jpg)

GRAPHIC (tm2613842d1_ex99-1img026.jpg)

GRAPHIC (tm2613842d1_ex99-1img027.jpg)

GRAPHIC (tm2613842d1_ex99-1img028.jpg)

GRAPHIC (tm2613842d1_ex99-1img029.jpg)

GRAPHIC (tm2613842d1_ex99-1img030.jpg)

GRAPHIC (tm2613842d1_ex99-1img031.jpg)

GRAPHIC (tm2613842d1_ex99-1img032.jpg)

GRAPHIC (tm2613842d1_ex99-1img033.jpg)

GRAPHIC (tm2613842d1_ex99-1img034.jpg)

GRAPHIC (tm2613842d1_ex99-1img035.jpg)

GRAPHIC (tm2613842d1_ex99-1img036.jpg)

GRAPHIC (tm2613842d1_ex99-1img037.jpg)

GRAPHIC (tm2613842d1_ex99-1img038.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2613842d1_8k.htm · Sequence: 1

false

0001526119

2026-05-07

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

May 7, 2026

Verastem,

Inc.

(Exact Name of Registrant as Specified in

Charter)

Delaware

001-35403

27-3269467

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

117 Kendrick Street, Suite 500, Needham, MA

02494

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including

area code: (781) 292-4200

(Former Name or Former Address, if Changed

Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under

the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under

the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under

the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common stock, $0.0001 par value per share

VSTM

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging

growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities

Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ¨

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure

On May 7, 2026, Verastem, Inc.

posted its updated corporate presentation on its website, a copy of which is furnished hereto as Exhibit 99.1 to this Current Report

on Form 8-K.

Item 9.01 Financial Statements and Exhibits

Exhibit No.

Description

99.1

Corporate Presentation,

dated May 7, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VERASTEM, INC.

Dated: May 7, 2026

By:

/s/ Daniel W. Paterson

Daniel W. Paterson

Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2613842d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Delivering Novel

Therapies for

RAS/MAPK Pathway-Driven Cancers

C O R P O R A T E P R E S E N T A T I O N

M A Y 2 0 2 6

FORWARD-LOOKING STATEMENTS

This presentation includes forward-looking statements about, among other things, Verastem Oncology’s (the “Company”) programs and product candidates, strategy, future plans and prospects, including statements related to the approval and commercialization of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) as a treatment for adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant-type (mt) recurrent Low-Grade Serous Ovarian Cancer (LGSOC), the expected outcome and benefits of collaborations, including with GenFleet Therapeutics (Shanghai), Inc. (GenFleet), including the conduct of a Phase 1/2a study and subsequent studies with respect to VS-7375, the potential of the results of the RAMP 301 Phase 3 trial to confirm the results of the RAMP 201 study specific to KRAS mutant patients and to expand the indication for AVMAPKI FAKZYNJA CO-PACK regardless of KRAS mutation status, the structure and potential clinical value of our completed, planned and pending clinical trials, the potential clinical value of various of the Company's clinical trials, including the RAMP 201, RAMP 201J, RAMP 205, RAMP 301 and VS-7375 trials, the timing of commencing and completing trials,

including topline data reports, our interactions with regulators, the timeline and indications for clinical development, regulatory submissions and the potential for and timing of commercialization of our product candidates and potential for additional development programs involving the Company’s lead compound and the potential market opportunities thereof; and the estimated addressable markets for, and anticipated market opportunities of our drug candidates. The words "anticipate," "believe," "estimate," "expect," "may," "plan," "target," "potential," "would," "could," "should," "continue," “can” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement.

Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to: the assumptions underlying the forward-looking statements; risks related to the development and successful commercialization of our product candidates; obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections; the challenges with the commercialization of a new product; our history of operating losses and the possibility that we may never achieve or maintain profitability; risks associated with meeting the objectives of Verastem's clinical trials, including, but not limited to Verastem's ability to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes objectives and/or timing objectives for Verastem's trials; any delays or failures enrollment and the occurrence of adverse safety events; our ability to successfully commercialize AVMAPKI FAKZYNJA CO-PACK in the U.S. including our ability to generate market demand for and acceptance of AVMAPKI FAKZYNJA CO-PACK; the potential inability to raise sufficient capital to fund ongoing operations as currently planned or to obtain financing on acceptable terms or to fund operations from revenues generated by the sales of AVMAPKI FAKZYNJA CO-PACK; actions or advice of regulatory agencies to maintain regulatory approval of AVMAPKI FAKZYNJA CO-PACK; the impact of current and future healthcare reforms, including those affecting the delivery of or payment for healthcare products and services; uncertainties related to the activities and initiatives of the current U.S. presidential administration, including regulatory and policy changes that may adversely affect our business; risks related to our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; decisions by regulatory authorities regarding trial design, labeling and other matters that could affect the timing, availability or commercial potential of our product candidates; whether preclinical testing of our product candidates and preliminary or interim data from clinical trials will be predictive of the results or success of ongoing or later clinical trials; that the timing, scope and rate of reimbursement for our product candidates is uncertain; that the market opportunities of our drug candidates are based on internal and third-party estimates which may prove to be incorrect; that third-party payors (including government agencies) may not reimburse; that there may be competitive developments affecting our product candidates; that data may not be available when expected; that enrollment of clinical trials may take longer than expected; the risks that we will not satisfy our post-marketing requirements and commitments established and agreed to as part of the FDA's approval of AVMAPKI FAKZYNJA CO-PACK; that our marketed product candidates may cause adverse safety events and/or unexpected concerns may arise from additional data or analysis, or result in unmanageable safety profiles as compared to their levels of efficacy; that we may not be able to confirm the results from the RAMP 201 study or expand the approved indication for AVMAPKI FAKZYNJA CO-PACK; that our product candidates may experience manufacturing or supply interruptions or failures; that any of our third-party contract research organizations, contract manufacturing organizations, clinical sites, or contractors, among others, who we rely on may fail to fully perform; that we face substantial competition, which may result in others developing or commercializing products before or more successfully than we do which could result in reduced market share or market potential for our product candidates; that we may be unable to successfully initiate or complete the clinical development and eventual commercialization of our product candidates; that the development and commercialization of our product candidates may take longer or cost more than planned, including as a result of conducting additional studies or our decisions regarding execution of such commercialization; that we may not attract and retain high quality personnel; that we or Pfizer, Inc. may fail to

fully perform under the license agreement covering certain Pfizer FAK inhibitors, including defactinib; that we or Chugai Pharmaceutical Co., Ltd. may fail to fully perform under the avutometinib license agreement; that we or GenFleet may fail to fully perform under the collaboration and option agreement covering VS-7375 and other assets we may decide to option in; that our total addressable and target markets for our product candidates might be smaller than we are presently estimating; that we or Secura Bio, Inc. may fail to fully perform under the asset purchase agreement with Secura Bio, Inc., including in relation to milestone payments; that we may not be able to establish new or expand on existing collaborations or partnerships, including with respect to in-licensing of our product candidates, on favorable terms, or at all; that we may be unable to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity, debt financing or otherwise; that we may not pursue or submit regulatory filings for our product candidates; that, due to the current presidential administration's significant reduction in the FDA's workforce and potential reductions to the FDA's budget, we may experience a material impact to the FDA's ability to engage in a variety of activities that may affect our business, including routine regulatory and oversight activities; and that our product candidates may not receive regulatory approval, become commercially successful products, or result in new treatment options being offered to patients.

Other risks and uncertainties include those identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission (SEC) on March 04, 2026, and in any subsequent filings with the SEC, which are available at www.sec.govand www.verastem.com.The forward-looking statements in this presentation speak only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements whether as a result of new information, future events or otherwise, except as required by law. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential

investors, and others should give careful consideration to these risks and uncertainties.

USE OF NON-GAAP FINANCIAL MEASURES

This presentation contains references to our non-GAAP operating expense, a financial measure that is not calculated in accordance with generally accepted accounting principles in the US (GAAP). This non-GAAP financial measure excludes certain amounts or expenses from the corresponding financial measures determined in accordance with GAAP. Management believes this non-GAAP information is useful for investors, taken in conjunction with the Company’s GAAP financial statements, because it provides greater transparency and period-over-period comparability with respect to the Company’s operating performance and can enhance investors’ ability to identify operating trends in the Company’s business. Management uses this measure, among other factors, to assess and analyze operational results and trends and to make financial and operational decisions. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the Company’s operating results as reported under GAAP, not in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. In addition, this non-GAAP financial measure is unlikely to be comparable with non-GAAP information provided by other companies. The determination of the amounts that are excluded from non-GAAP financial measures is a matter of management judgment and depends upon, among other factors, the nature of the underlying expense or income amounts. Reconciliations between this non-GAAP financial measure and the most comparable GAAP financial measure are included in the footnotes to the slides in this presentation on which such non-GAAP number appears.

THIRD-PARTY SOURCES

Certain information contained in this presentation, including industry and market data and other statistical information, relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company’s own

internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions.

Disclaimers

OUR COMMERCIAL

PRODUCTS

MONOTHERAPY & COMBINATION APPROACHES

RAS: Rat Sarcoma Virus; MAPK: Mitogen-Activated Protein Kinase; RAF: Rapidly Accelerated Fibrosarcoma; MEK: Mitogen-Activated Extracellular Signal-regulated Kinase; FAK: focal adhesion kinase;

KRAS: Kirsten Rat Sarcoma Virus

Please see the full Prescribing Information for more information

OUR FOCUS

To expeditiously develop and deliver transformative therapies that truly change outcomes

for people living with RAS/MAPK pathway-driven cancers.

Avutometinib

RAF/MEK Clamp

Defactinib

FAK Inhibitor

VS-7375

KRAS G12D (ON/OFF)

Inhibitor

Verastem Oncology: Tackling Challenging Cancers with Novel Therapies

FDA: Food and Drug Administration

CLINICAL-TO-COMMERCIAL SUCCESS

in bringing novel RAS/MAPK

pathway-targeted therapies

from development to FDA

approval to

commercialization

INNOVATIVE

PIPELINE

with a potential best-in-class KRAS G12D asset

targeting the most

prevalent KRAS mutation in

human cancers

SCALABLE

ORGANIZATION

to maximize future

oncology development

programs and launches

Well Positioned to Deliver Continued Commercial Success and a Potential

Best-in-Class Treatment for Long-term Growth

OUR ADVANTAGE:

TARGET

RAS DIRECTLY

TARGET THE

PATHWAY

DOWNSTREAM

TARGET THE PARALLEL

PATHWAY THAT

DRIVES RESISTANCE

First novel/novel

combination therapy,

targeting the

RAS/MAPK pathway,

approved in oncology

Precision Targeting of RAS/MAPK-Driven Cancers Differentiates Our Science

OUR SCIENTIFIC STRATEGY:

EGF: Epidermal Growth Factor; EGRF: Epidermal Growth Factor Receptor; ERK: Extracellular Signal-regulated Kinase; PI3K: Phosphatidylinositol 3-Kinase; AKT: Protein Kinase B; mTOR: Mammalian

Target of Rapamycin; YAP: Yes-Associated Protein; TEAD: Transcriptional Enhanced Associate Domain; MYC: Myelocytomatosis oncogene

ICT: investigator choice of treatment; LGSOC: Low-grade Serous Ovarian Cancer; mPDAC: metastatic Pancreatic Ductal Adenocarcinoma; mNSCLC: metastatic Non-small cell lung cancer; mCRC: 6

metastatic colorectal cancer; FAKi: focal adhesion kinase inhibitor; Gem: Gemcitabine. NabP: nab-paclitaxel; EGFR: epidermal growth factor receptor

Not shown: *GenFleet Therapeutics has an ongoing Phase 1/2 and Phase 3 clinical trials in China with VS-7375, known as GFH375 in China. GenFleet retains greater China rights. Verastem has two

undisclosed assets at discovery phase targeting RAS/MAPK pathway-driven cancers as part of the GenFleet collaboration.

Asset Disease Phase Key Milestones

Avutometinib, RAF/MEK Clamp + Defactinib, FAKi

Recurrent LGSOC Avutometinib

+ Defactinib

Expect to report topline readout

of primary endpoint by mid-2027

Recurrent LGSOC Avutometinib

+ Defactinib vs ICT

Expect to report an update on

the expansion cohort in Q2’26 1L mPDAC Avutometinib

+ Defactinib + Gem/NabP

VS-7375, oral KRAS G12D (ON/OFF) inhibitor

Ongoing enrollment; expect to

report early data in 1H’26; report

update in 2H’26

KRAS G12D-mutated

solid tumors (advanced solid

tumors)

VS-7375 monotherapy +

various combinations

Expect FPI in mid-2026 2L mPDAC; 1L PDAC

combination

VS-7375 monotherapy

+ EGFR combination

Expect FPI in mid-2026

2L/3L advanced NSCLC; 2L+

asymptomatic untreated brain

mets

VS-7375 monotherapy

Expect FPI in mid-2026 2L+ mCRC; 1L mCRC

combination

VS-7375 combinations

w/ EGFR & Chemotherapy

TARGET-D 101: Phase 1/2

dose escalation & expansion

TARGET-D 202: Phase 2 registration directed trial

TARGET-D 203: Phase 2 registration directed trial

TARGET-D 201: Phase 2 registration directed trial

RAMP 201: Phase 2 Registration Directed Trial;

Accelerated FDA Approval May 2025

RAMP 301: Phase 3 International Confirmatory Trial

RAMP 205: Phase 1/2 Trial

Multi-Faceted & Targeted Approaches to Address RAS/MAPK-Driven Cancers

OUR PIPELINE:

MAXIMIZE COMMERCIAL LAUNCH

EXECUTION OF AVMAPKI® FAKZYNJA®

CO-PACK FOR BROAD HCP ADOPTION

Commercial Product and Pipeline Positioned to Deliver Long-Term

Shareholder Value

OUR 2026 PRIORITIES:

CONTINUE EXECUTION OF RAMP 301

CONFIRMATORY PHASE 3 TRIAL

IN RECURRENT LGSOC

MAINTAIN STRONG BALANCE SHEET

HCP: Healthcare professional

GENERATE MONOTHERAPY &

COMBINATION DATA WITH VS-7375 TO

INFORM REGISTRATION PATH IN KRAS

G12D-MUTATED SOLID TUMORS

1H2026 Mid-2026 2H 20206

Continued strong execution of product commercialization throughout 2026 building upon

successful product launch

Q2 2026: Report an update on the safety & efficacy of the

expansion cohort with six months of follow-up on all

patients

RAMP 205 1L PDAC

Avutometinib + Defactinib +

Gem/NabP

2H 2026: Report update on

TARGET-D 101

1H 2026: Report early data from the

TARGET-D 101 Phase 1/2 trial

VS-7375 TARGET-D 101

Dose escalation & expansion

Monotherapy & Combinations

(advanced solid tumors)

Expect FPI in mid-2026

VS-7375 TARGET-D 201

2L mPDAC monotherapy +

combination; 1L mPDAC

combination

Expect FPI in mid-2026

VS-7375 TARGET-D 202

2L/3L advanced NSCLC

monotherapy; 2L+ asymptomatic

untreated brain mets

Expect FPI in mid-2026

VS-7375 TARGET-D 203

2L+ mCRC combination; 1L mCRC

combination

Milestones for 2026

OUR MILESTONES:

FPI: First Patient In.

Commercially Launched

in the U.S. for KRAS-mutated

Recurrent LGSOC

FDA APPROVAL DATE: MAY 8, 2025

70% of LGSOC Tumors are Driven by the RAS/MAPK Pathway;

~30% of These Have a KRAS Mutation1,2,3,4

• Avutometinib inhibits MEK kinase activity while

blocking the compensatory reactivation of MEK

by upstream RAF5,6,7

• Blocking RAF and/or MEK activates FAK, a key

mediator of drug resistance8,9

• Defactinib, a FAK inhibitor, inhibits parallel

pathway signaling10,11,12

• Together, avutometinib plus defactinib offer

more complete blockade of the signaling that

drives the growth of RAS/MAPK pathway-dependent tumors

RAF-MEK

Complex

The Combination of Avutometinib and Defactinib

Induces Deeper Inhibition of Tumor Growth

1. AACR Genie v16.1; 2. Cheasley et al., J Pathol 2021; 3. Thomson et al., Gynecol Oncol 2023;

4. Gershenson et al., Gynecol Oncol 2022; 5. Coma et al., AACR 2022; 6. Ishii et al., Cancer Res, 2013;

7. Lito et al., Cancer Cell, 2014; 8. Lubrano et al., AACR 2024; 9. Banerji et al., AACR 2020; 10. Jones et al.,

Invest New Drugs 2015; 11. McNamara et al., Gynecol Oncol 2024; 12. Banerjee et al., ASCO 2023

ERK: Extracellular Signal-regulated Kinase; FAK: Focal Adhesion Kinase; MEK, Mitogen-Activated

Extracellular Signal-regulated Kinase; mTOR: Mammalian Target of Rapamycin; P: Phosphate; PI3K:

Phosphatidylinositol 3-Kinase; RAF: Rapidly Accelerated Fibrosarcoma; RAS: Rat Sarcoma Virus; RhoA: Ras

Homolog Family Member A; RTK: Receptor Tyrosine Kinase; YAP: Yes-Associated Protein.yes

High Unmet Need for an Effective and

Tolerable Therapy in Recurrent LGSOC

• U.S. annual incidence: ~1,000-2,0001

and

prevalence: 6,000-8,0002

• Affects younger women with bimodal peaks

of diagnosis between the ages of 20-30 and

50-60

– Disproportionately impacts health, fertility, and

long-term quality of life3,4

• 80-90% of patients will experience a

recurrence5

• Standard of care offers low to moderate

response rates (6-13%)6,7,8

When you get told that you have a recurrence,

the mental load is a lot. You’re thinking, okay,

what did I have to do for treatment the first

time? Now I have to repeat that. And will there

even be something available for me to take for a

second, or a third recurrence? - Amanda, real patient living with recurrent LGSOC;

diagnosed at 26 with LGSOC

1.Verastem DOF; 2. US Cancer Statistics. Accessed 2024; 3. Slomovitz Gynecol Oncol 2020;

4. Manning-Geist B et al. Clin Cancer Res 2022;28(20):4456-4465; 5. Babaier 2022/p1/para1/ln6,7;

6. Gershenson Gynecol Oncol 2022; 7. Slomovitz Gynecol Oncol 2020; 8. Monk 2020/p3758/table2/footnote-b; 11

Driving Impact in the First Year of Launch

N E T P R O D U C T R E V E N U E

S I N C E L A U N C H

$11.2M

$17.5M

$2.1M

$30.9M

FY25

$18.7M

Q2’25* Q3’25 Q4’25 Q1’26

400+

unique U.S. prescribers through April 2026

60/40

of prescription split between GynOncs and MedOncs

65%

of commercially eligible patients

are using our copay program

12-14

days to fill prescriptions

$18. 7M in Net Product Revenue in Q1’26

Achieved ~$50M in AVMAPKI FAKZYNJA CO-PACK

Net Product Revenue Since Launch in May 2025

*Not a full quarter; May 8, 2025 FDA approval

Verastem DOF; US dollars in millions. Refer to press release issued on May 7, 2026 for full financial details.

Please see the full Prescribing Information for more information

Three Key Drivers to Realize Full Benefits of AVMAPKI FAKZYNJA CO-PACK

New

Patients

Starts

Use at

First

Recurrence

Help

Patients Stay

on Therapy

Please see the full Prescribing Information for more information

Reach among

prescribers who

haven’t prescribed

AVMAPKI FAKZYNJA

CO-PACK

Experience with

AVMAPKI FAKZYNJA

CO-PACK among

current prescribers

Entrenched

prescribing behaviors

Maximizing Benefit with AVMAPKI FAKZYNJA CO-PACK at First Recurrence

Expand Shift Deepen

Substantial Market Opportunity, Growth Potential Ahead

Please see the full Prescribing Information for more information

RAMP 201: Demonstrated Durable Results Across Various Efficacy Measures

in Heavily Pretreated Patients With and Without a KRAS Mutation

Avutometinib + Defactinib Regimen: Best Overall Response

82% of All Patients Had a Reduction in Target Lesions,

Regardless of KRAS Status1

All Patients KRAS mt KRAS wt 1

ORR % 31% 44% 17%

DoT, mean 14.5 months 18 months 11 months

DoR, median 31 months 31 months 9 months

PFS, median 13 months 22 months 13 months

61% 70% 50% DCR at 6 or

more months

10% Discontinuation Rate

Due to AEs

1. RAMP 201 data cut off as of June 30, 2024; 2. RAMP 201 Long-Term Efficacy and Safety August 2025 data cut off presented at SGO 2026. ORR: Objective Response Rate; DoT: Duration of Treatment; mDoR:

median Duration of Response; mPFS: media Progression-free Survival; DCR: Disease Control Rate; AE: adverse event

Avutometinib + Defactinib Regimen: Best Overall Response • More than half of responders (56%) remain in response at 24 months • KRAS mt patients: mDoR remains at 31.1 months and mPFS is 19.6 months • KRAS wt patients: mDoR is now 12 months and mPFS is 12.7 months

The discontinuation rate due to

adverse events remains low (12%)

even with extensive follow up

RAMP 201 Long-Term Data

Median Follow-Up

of 2 Years2

NEW DATA

PFS by RECIST v1.1

per INV assessment

ORR

DoR

DCR

Safety

Pharmacokinetics

PROs a Unless otherwise specified, all tumor

response-based endpoints will be

analyzed using both BICR and INV

assessments

*US FDA analysis plan will evaluate PFS independently in KRAS-mt and KRAS wt LGSOC; BID: twice a day; BIW: twice a week; DCR: disease control rate; DoR: duration of response; INV: investigator;

KRAS: kirsten rat sarcoma virus; MEKi: MEK inhibitor; mt: mutant; PO: per oral; pts, patients; ORR: objective response rate; OS: overall survival; PD: progressive disease; PFS: progression-free survival;

PROs: patient-reported outcomes; RECIST: response evaluation criteria in solid tumors; wt: wild type. BICR: blinded independent central radiological review

• Expect to report topline primary endpoint of PFS by mid-2027

• Similar entry criteria to RAMP 201 patient population, KRAS mt and KRAS wt recurrent LGSOC

• Study sites include the U.S., Canada, UK, Europe, Australia, New Zealand, Japan and South Korea

• Recurrent disease after prior

platinum therapy

• Documented KRAS mutation status

• Measurable disease per RECIST v1.1

• Confirmed LGSOC diagnosis

• Prior MEKi allowed

• Prior bevacizumab allowed

RAMP 301 (GOG-3907/ENGOT-ov81/GTG-UK): NCT06072781

Pegylated Liposomal Doxorubicin

Paclitaxel

Letrozole

Anastrozole

Investigator’s Choice

n = 135

Avutometinib 3.2 mg PO BIW

Defactinib 200 mg BID

3 weeks on, 1 week off

Avutometinib + Defactinib

n = 135

May cross over upon

BICR-confirmed PD

PFS (BICR by RECIST v1.1)

Hierarchical Evaluation of PFS*:

KRAS mutant LGSOC

All recurrent LGSOC

KRAS wt LGSOC

Primary Endpoint:

Secondary Endpointsa 1:1 Randomization

n = 270

Stratification Factors: • KRAS mutation status

(wt vs. mt) • Geography (N.

America/EU) vs. ROW

• Number of prior

therapies (1-3 vs.

4 or more)

Inclusion Criteria

RAMP 301: International Phase 3 Confirmatory Trial of

Avutometinib + Defactinib in Recurrent LGSOC

U.S.

Secured FDA

Accelerated Approval

in KRAS-mutated

recurrent LGSOC.

2029

2025

RAMP 301: topline data

expected in mid-2027.

U.S. Label Expansion

Leverage the RAMP 301

results to confirm the initial

indication and expand the

indication regardless of

KRAS mutation status.

Japan:

Leverage the results from

RAMP 201J & RAMP 301 for

potential approval in both

KRAS mutant and

wild type recurrent LGSOC.

Europe:

Leverage results from

RAMP 301 for potential

approval in both KRAS

mutant and wild type

recurrent LGSOC.

2028

2027

KRAS MT represents ~33% of the population, while the WT represents 67% and therefore there are many more addressable patients.

Potential for Label and Geographic Expansion

AVMAPKI FAKZYNJA CO-PACK Future Commercial Opportunity

VS-7375,

Oral KRAS G12D

(ON/OFF) Inhibitor

19 Ref: Lee et al Nature, Dec 2022 for epidemiology; 1: VSTM DOF, based on internal estimates; 2: McIntyre et al., Cancer Cell 2024, 42:1614-1629 and Hafezi S et al., Int J Mol Sci

2021, 22(19):10219; 3: Judd J, Abdel Karim N, Khan H, et al. Mol Cancer Ther. 2021;20(12):2577-2584;4: Lee J, et al. J Clin Med. 2020;9(12):3863; BTC: biliary tract cancers

KRAS G12D: The Most Prevalent KRAS Mutation in Cancer with Poor

Prognosis and High Unmet Need

PANCREATIC

40%

KRAS G12D

mutation in

pancreatic cancer

correlates with

worse outcomes,

shorter survival,

and a higher risk of

progression2

LUNG

KRAS G12D

mutation is a

significant driver in

lung cancer,

especially among

non-smokers, and

is linked to poor

responses to SOC3

COLORECTAL

15%

KRAS G12D

mutation in CRC is

often linked to

more aggressive

tumors4

TUMOR

AGNOSTIC

16% - Small Bowel

7-15% - BTC

5% - Endometrial

KRAS G12D

mutation appears

across many

cancer types and

remains an unmet

medical need

KRAS G12D Mutation Expression Across Tumor Types

60,000+ New Patients in U.S. Annually1

Data in China Phase 1/2 study demonstrate strong monotherapy

response rates in patients with previously treated pancreatic and

lung cancers with manageable tolerability

Pachter et al., Targeting RAS 2nd edition 2025; Ai et al., ASCO 2025; Li et al., World Conference of Lung Cancer 2025; pERK: phosphorylated Extracellular signal-regulated

Kinase; GEF: Guanine nucleotide exchange factor GAP: GTPase-activating protein

VS-7375: Potential Best-in-Class G12D Inhibitor for Advanced KRAS G12D-Mutated Cancers

Differentiated Profile vs. Other RAS Inhibitors

• Dual potent inhibition of both ON and OFF states of KRAS G12D – Correlates with better in vivo efficacy and durability vs. ON-only

RAS inhibitors • High affinity for KRAS G12D with long residence time (18-24 hours) – Correlates with more rapid and durable suppression of pERK signaling

vs. RMC-9805 in tumor cell lines

• Selective inhibition of KRAS G12D – Spares T cell proliferation in contrast to RAS-Multi inhibitor, which

impairs T cell proliferation

• Once daily oral dosing in patients – Achieves exposures corresponding to maximal tumor regressions

across preclinical models

RMC-6236 and RMC-9805 are assets developed by Revolution Medicine; AMG410 is an asset developed by Amgen; AZD0022 is an asset developed by AstraZeneca. 21

VS-7375: Best-in-Class Preclinical Profile

LS513 Colorectal Cancer Model

Better Efficacy and Durability than G12D ON and Pan-RAS

ON Inhibitors in KRAS G12D Mutant Tumor Models

Isolated CD3+ T cells from PBMCs from triplicate

human donors were cultured with anti-human

CD3/CD28 beads and treated for 3 days

Variant-Selective KRAS

Inhibitors Spare T Cell

Proliferation in Contrast to

RAS-Multi Inhibitor

Assay VS-7375

IC50 (nM)

KRAS G12D

State

RAF1

binding 2 1 GppNHp-bound

(ON/active)

Nucleotide

exchange 6 1 GDP-bound

(OFF/inactive)

Assay VS-7375

KD (pM)

KRAS G12D

State

18 SPR affinity GppNHp-bound

(ON/active)

12 SPR affinity GDP-bound

(OFF/inactive)

Functional Assays

Potent Dual ON/OFF Inhibitor

of KRAS G12D

Long Residence time (18-24 hours)

for VS-7375 vs ~1 hour for AZD0022

(G12Di) or AMG410 (pan-RASi)

KP4 Pancreatic Cancer Model LU0876 NSCLC PDX Model

Binding Assays

CD8+

CD4+

GFH375/VS-7375 Confers Single Agent Anti-Tumor Activity in Patients with

Previously Treated PDAC and NSCLC

PDAC

• 58.3% ORR (n=12) in 2L; 40.7% ORR (n=59) in all evaluable pts at 600 mg QD* • mPFS and mOS has not been reached for 2L PDAC pts. Median follow up time was 5.65 months. C -PR confirmed → -On treatment

NSCLC

• 68.8% ORR (n=16) at 600 mg QD; 57.7% ORR (n=26) evaluable pts* • Among the 5 pts with baseline brain metastases, 2 achieved PR

Ongoing Trials by GenFleet in China • Initiated registrational Phase 3 trial in previously treated KRAS G12D-mutated PDAC at 600 mg QD versus investigator choice of chemotherapy

• Ongoing Phase 1b/2 trial of GFH375 in combination with cetuximab or

chemotherapy. The chemotherapy combination will be conducted 1L PDAC. • Ongoing Phase 1/2 trial in G12D solid tumors

Manageable Safety Profile

• GFH375 presented a manageable safety profile at 600mg QD in

heavily previously treated KRAS G12D mutant NSCLC & PDAC patients

• NSCLC: 4.2% of patients discontinued treatment due to TRAEs.

Dose intensity = 90%. • PDAC: 3% of patients discontinued treatment due to TRAEs.

Dose intensity = 93%

600mg QD

(N=16)

All patients

(N=26)

ORR [90% CI] 57.7% [39.8%, 74.2%] 68.8% [41.3%, 89.0%]

DCR [90% CI] 88.5% [72.8%, 96.8%] 93.8% [69.8%, 99.8%]

3L+

(N=47)

(N=12)

All PDAC

(N=59)

40.7% [29.87%, 52.22%] 58.3% [31.52%, 81.90%] 36.2% [24.52%, 49.18%] ORR

[90%CI]

96.6% [89.71%, 99.39%] 100% [77.91, 100%] 95.7% [87.20%, 99.24] DCR

[90%CI]

GFH375 is being developed by GenFleet Therapeutics in China. Source of data: GenFleet presentation at WCLC, ESMO and company event in 2025. *Includes confirmed and

unconfirmed responses. QD: once daily; PR: partial response; TRAE: treatment related adverse events; IL: first-line; 2L: second line; 3L: third-line;

Strong Partner Data (GenFleet)1

• Activity in pre-treated PDAC &

NSCLC

• 2L PDAC: 58% ORR (n=12) • 2L+ NSCLC: 69% ORR (n=16) • 300+ patients treated in China

• Enabled U.S. trial start at 400 mg QD

• Ongoing Phase 1/2 & Phase 3 trial in

China • BTD received in China for NSCLC &

PDAC

Ex-US Data Provides Roadmap

U.S. Trial: Emerging Favorable Safety

& Tolerability Profile2

• No drug-related liver toxicity or

neutropenia observed

• Monotherapy: DLT cleared up to

900 mg QD dose level, expansions

ongoing; 1200 mg QD under

evaluation

• Combinations: DLT cleared up to

600 mg QD with cetuximab &

evaluating higher dose; ongoing

combo with GnP; ongoing combo

with Pembro-Platinum-Pemetrexed

Building Clinical Evidence to Become the Preferred Agent for KRAS G12D-mutated Cancers

Path to Accelerated Approval

Continuing Dose Escalation &

Combination Evaluations

• Phase 2 trials designed to support

Accelerated Approval • FPI expected by mid-2026

2L PDAC

2L/3L NSCLC

2L+ CRC

1. GenFleet Therapeutics is developing VS-7375 in China as GFH375. GenFleet presentations at WCLC, ESMO and company event in 2025. Includes confirmed and unconfirmed

responses. 2. As of a January 30, 2026 safety data cutoff from the TARGET-D 101 trial.

DLTs: Dose-limiting Toxicities; ORR: Objective Response Rates; QD: daily dose; FPI: First Patient in. GnP: Gemcitabine and Nab-paclitaxel

24 NCT07020221

D1: 2L+ CRC

VS-7375 600mg QD

+ Cetuximab Ongoing

D2: 1L NSCLC

Carboplatin/Pemetrexed

/Pembrolizumab

D3: 1L PDAC

Gemcitabine/Nab-P

Early Observations Show Manageable Safety & Tolerability

Profile with Promising Anti-Tumor Activity

Enrolling

Monotherapy Combination Therapy

Part B:

Dose Expansion

Part C:

Combination Dose

Escalations Cohorts

Part D:

Combination Dose

Expansions Cohorts

Part A:

Dose Escalation

Solid tumors

Dose Level 2:

600 mg QD

Dose Level 3:

900 mg QD

Dose Level 1:

400 mg QD

Dose Level 4:

1200 mg QD

Dose-Level Cleared

The study is dosing with meals and using prophylactic anti-emetics

Dose

Selection

Dose

Selection

Dose

Selection

C1: 2L+ Solid Tumors

VS-7375 900mg QD +

Cetuximab Ongoing

C2: 1L NSCLC

Carboplatin/

Pemetrexed/

Pembrolizumab

C3: 2L PDAC

Gemcitabine +

Nab-Paclitaxel

Cohort B3:

2L+ Tumor Agnostic

Solid Tumors

Cohort B2:

2L/3L NSCLC

Cohort B1:

2L PDAC

25 VSTM DOF April 2026; AUCss: area under the curve at steady state

400 mg 600 mg 900 mg

100

1000

10000

900 mg QD of VS-7375 Achieves the Targeted Human AUCss in All Patients

Corresponding to Maximal Tumor Regression across Mouse Models VS-7375 (ng*h/mL)

600mg QD

VS-7375-101

(TARGET-D 101)

n=11 n=49 n=8

GenFleet Study

400mg QD 600mg QD 900mg QD

Equivalent exposure to mice at 100 mg/kg

(PR in almost all mice in 4 tumor models)

Equivalent exposure to mice at 10 mg/kg

(Tumor regression in sensitive tumor models)

Equivalent exposure to mice at 30 mg/kg

(Tumor regression in all tumor models)

Monotherapy Dose Escalation Cohorts (All dose levels)

N=231

; mDoT, median (range): 1.6 (0.7-5.6) months (TRAEs)

Gr. 1, n (%) Gr. 2, n (%) Gr. 3, n (%) Gr. ≥4, n (%) All Gr., n (%) System Organ Class

Preferred Term

Gastrointestinal

Nausea 11 (48) 1 (4) 0 (0) 0 (0) 12 (52)

Diarrhea 7 (30) 1 (4) 1 (4) 0 (0) 9 (39)

Vomiting 6 (26) 0 (0) 0 (0) 0 (0) 6 (26)

Abdominal pain 0 (0) 1 (4) 0 (0) 0 (0) 1 (4)

Abdominal distention 2 (9) 0 (0) 0 (0) 0 (0) 2 (9)

Flatulence 2 (9) 0 (0) 0 (0) 0 (0) 2 (9)

General

Fatigue 6 (26) 1 (4) 0 (0) 0 (0) 7 (30)

Edema peripheral 1 (4) 0 (0) 0 (0) 0 (0) 1 (4)

Investigations

AST increased 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)

ALT increased 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)

Blood bilirubin increased 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)

GGT increased 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)

ALP increased 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)

Amylase increased 1 (4) 1 (4) 1 (4) 0 (0) 3 (13)

Lipase increased 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)

Blood & lymphatic/ investigations

Anemia 1 (4) 1 (4) 0 (0) 0 (0) 2 (9)

Neutropenia 1 (4) 1 (4) 0 (0) 0 (0) 2 (9) 2 WBC decreased 0 (0) 1 (4) 0 (0) 0 (0) 1 (4)

Platelet decreased 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)

Metabolism and nutrition

Decreased appetite 2 (9) 1 (4) 0 (0) 0 (0) 3 (13)

Nervous system

Dizziness 1 (4) 0 (0) 0 (0) 0 (0) 1 (4)

Headache 1 (4) 0 (0) 0 (0) 0 (0) 1 (4)

Skin & subcutaneous tissue

Rash maculo-papular 1 (4) 0 (0) 0 (0) 0 (0) 1 (4)

VSTM DOF, Jan. 30. 2026 cutoff; mDOT: median Duration of

Treatment; AST: AspartateAminotransferase; ALT: Alanine

Aminotransferase;GGT: Gammaglutamyl transferase; ALP:

AlkalinePhosphatase; WBC: White Blood Count; Gr: Grade

1. 9 patients at 400mg, 9 patients at 600mg, 5 patients at 900mg

2. Included neutropenia and neutrophil count decreased

• No drug-related liver function test

abnormalities were reported in any

patient across any of the dose levels

evaluated

• No neutropenia >Grade 2

was reported

• Rates of nausea, vomiting and

diarrhea, using standard prophylactic

anti-nausea agents and rapid

institution of over-the-counter anti-diarrheals, are lower than those

reported by our partner in China

VS-7375 Safety/

Tolerability Profile

*All A1 pts with SD allowed to crossover to cetuximab combo if A1 fails to meet efficacy threshold

Maximizing the Opportunity in PDAC Through VS-7375

Monotherapy and EGFR Combination Strategies

R 1:1 randomization

Part A: 2L PDAC

Cohort

VS-7375 900 mg

monotherapy

(N=20)

VS-7375 900 mg +

Cetuximab

(N=20)

Cohort

VS-7375 900 mg

monotherapy

(N=60)

VS-7375 900 mg +

Cetuximab

(N=60)

Part B: 2L PDAC Expansion

Cohort(s) that meet

efficacy threshold* Part C: 1L PDAC

VS-7375 900 mg + Cetuximab

(N=25)

Study Population Key Endpoints Next Key Milestone

FPI Expected

Mid-2026

Part A, B, C:

Primary: ORR by BICR

Secondary: DOR

Part A & B: 2L KRAS

G12D-mutated PDAC

Part C: 1L KRAS

G12D-mutated PDAC

EGFR: Epidermal Growth Factor Receptor

Evaluating VS-7375 Monotherapy in Advanced

NSCLC, Including Patients with Brain Metastases

Cohort A:

Confirm

900 mg QD is the

go-forward dose

Part A: 2L/3L NSCLC

VS-7375 900 mg QD

(N=20) Cohort B: Preferred dose of VS-7375

(N=60)

Part B: 2L/3L NSCLC

Part C: 2L/3L/4L

VS-7375 900 mg QD

with asymptomatic untreated brain

metastasis

(N=25)

Next Key

Milestone Study Population Key Endpoints

FPI Expected

in Mid-2026

Primary: ORR by BICR

Secondary: DOR

• Prior treatment with platinum-based chemo and ICI • At least 1 and no more than 2

prior systemic lines of therapy

Parts

A & B:

Intracranial ORR by

mRECIST v1.1 by BICR

Received at least 1 and no more

than 3 prior systemic lines

of therapy

Part C:

#No prior TAS-102 (trifluridine and tipiracil) or regorafenib. VEGFi as appropriate.

Advancing a VS-7375 Combination Strategy with

EGFR Inhibitors and Chemotherapy in Metastatic CRC

Cohort

A1:

R Confirm

900 mg QD is the

go-forward dose

2:1 randomization

Cohort

A2:

Part A: 2L+ CRC

VS-7375 900 + Cetuximab or

Panitumumab

(N=40)

VS-7375 900 mg monotherapy

(N=20)

Cohort B:

Preferred Regimen:

VS-7375 + Cetuximab or

Panitumumab

VS-7375 monotherapy

(N=60)

Part C: 1L CRC

VS-7375 + Cetuximab + mFOLFOX6

(N=30)

Part B: 2L+ CRC

mFOLFOX: modified oxaliplatin, leucovorin, and 5-fluorouracil; VEGFI: vascular endothelial Growth Factor

Study Population Key Endpoints Next Key Milestone

FPI Expected in

Mid-2026

Primary: ORR by

BICR

Secondary: DOR

Prior SoC: fluoro-pyrimidine, irinotecan,

oxaliplatin, VEGFi#

Part

A, B:

Safety/Tolerability No prior tx for

metastatic disease Part C:

Development Focus on Highest Unmet Need Populations to Expedite

Regulatory Submissions

Complete single-agent

and combination dose

expansion cohorts

1H INTO

2H 2026

Initiate single-agent and

combination Phase 2

registration-directed studies

2H 2026

Pursue regulatory

approvals 2027 +

Topline Data from RAMP 205:

Avutometinib + Defactinib

+ Standard of Care in First-Line

Metastatic Pancreatic Cancer

Historical Gem/Nab mPFS

RAMP 205: Data Presented At ASCO 2025

Trial Status: • Dose Level 1 (DL1) chosen as RP2D for

expansion phase

– Avutometinib: 2.4 MG, Defactinib: 200 mg – Day 1-8-15, Gem: 800 mg NabP: 125mg

• Completed enrollment of 29 patients in

expansion phase

ASCO 2025 Data: • 83% (10/12) confirmed ORR in DL1 with tumor

shrinkage observed in all patients

• Encouraging duration of treatment observed

for DL1

• No new or unexpected AEs observed.

Most non-laboratory AEs were Grade 1 or 2 • AEs were generally manageable, allowing

patients to remain on treatment

Dose Level 1: Efficacy Evaluable Population (n=12)

Dose Level 1:

Duration of

Treatment Safety

Population

(n=12)

Historical Gem/Nab mPFS

Source: F_TR_WATERFALL.sas Data Cut: 01 AUG 25;

Source: Program: F_TX_RS_SWIMMER_DL1.sas Data Cut: 25 APR 25;

AE: adverse event; MG: milligram; Gem: gemcitabine; NabP: Nab-paclitaxel

Threshold

for PR Dose Level 1:

Response & Disease Control Rate

as of August 1, 2025

Confirmed ORR, n (%) 83.3% (10/12)

PR, n (%) 10 (83.3)

SD, n (%) 2 (16.7)

PD, n (%) 0

DCR, n (%) ≥ 4 cycles 92% (11/12) Best % Change in Target Lesion Sum of Diameters 40

-20

-40

-60

-80

-3.3

-14.1

-32.1 -32.9 -32.9

-38.7 -41.3 -42.8

-46.3 -46.3

-50.7

-74.7

SD SD cPR cPR cPR cPR cPR cPR cPR cPR cPR cPR

SD PD

SD PR

SD PR PR

PR PR

SD PR PR

SD SD

PR PR

SD PR PR PR

SD SD PR PR

SD SD PR

SD PR PR

PR PR PD

PR PD

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Treatment Duration (in months)

Continued Treatment

Financials

Oberland Finance Credit Facility

• Up to $150M available in a series of notes – $75M principal of notes outstanding

– Remaining $75M available at Company’s option upon achievement of pre-defined milestones

> $25M tranche upon FDA approval of avutometinib and defactinib for treatment of LGSOC

> $50M tranche upon trailing six months revenue of at least $55M

• Floating interest rate, subject to a floor and a cap

• Interest only payments through January 2031

• No financial covenants

Three Months

Ended March 31, 2026

Financial Summary

($ in millions)

Net Product Revenue $18.7M

GAAP Operating Expenses $63.6M

Non-GAAP Operating Expenses $61.5M* As of March 31, 2026

Cash, cash equivalents & short-term investments $181.7M

87.8M** Shares Outstanding

Q1 2026 Financial Results

* Three months ended March 31, 2026 GAAP operating expenses of $63.57M less Q1 2026 stock-based compensation expense of $2.05M = $61.52M Q1 2026 non-GAAP operating expenses.

** Excludes unexercised pre-funded warrants (12.2M shares upon exercise).

EU: European Union

Delivering for Long-term Growth

• Established commercial presence with AVMAPKI FAKZYNJA CO-PACK

– RAMP 301: Fully-enrolled Phase 3 confirmatory trial has the potential to expand U.S.

label and can be leveraged for EU/Japan approvals in recurrent LGSOC regardless

of KRAS mutation

• VS-7375 addresses significant opportunity in multiple KRAS G12D solid

tumors with a differentiated profile and best-in-class anti-tumor activity

– Active clinical development program advancing VS-7375 toward registration-directed studies in monotherapy and various combination approaches across

multiple KRAS G12D solid tumors; expect to report early data update in 1H 2026 • Cash runway into 2027 to see key data inflection points – AVMAPKI FAKZYNJA CO-PACK franchise will be self-sustaining in 2H 2026, funding

both commercial operations and avutometinib plus defactinib clinical trials

THANK YOU!

AVMAPKI FAKZYNJA CO-PACK: Category 2A Recommendation for KRAS-mutated Recurrent LGSOC

NCCN

Category 3

NCCN

Category 2b

NCCN

Category 2a

NCCN

Category 1

General %

Commercial

Payer Coverage

Binimetinib

• Study stopped early due to futility

• 16% ORR by BICR

• 31% discontinuation rate due to

AEs • Supported by MILO study3

Hormonal therapy

(e.g., Anastrozole, Letrozole)

& chemotherapy

• 6-13% ORR 4

• 17-30% discontinuation rate due

to AEs4

Trametinib

(2-4% US utilization rate1

) • 26% ORR by INV assessment, no BICR5

• 36% discontinuation rate due to AEs5

No category 1

recommendation

Examples of Clinical

Data in LGSOC and

Current NCCN

Guideline Category

Avutometinib + Defactinib

Combination Therapy

KRAS mt recurrent LGSOC

Please see the full Prescribing Information for more information

General source: NCCN; McGivney Global Advisory research and analysis; L.E.K. research and analysis. NCCN categories of preference: Preferred intervention, Other recommended intervention, Useful in certain circumstances.

High-level of evidence generally means large randomized controlled Phased 3 trials; Pie charts represent coverage by all major commercial players; 1. Data on File; 2. GOG 281 trial Gershenson et al., Lancet 2022; 3. MILO Study Monk et al., J Clin Oncol 2020; 4. Supported by GOG 281 and MILO studies2,3 ; 5. Supported by GOG 2812

;AEs: adverse events; BICR: Blinded Independent Central Review Cleaned up

(can just be stored as backup)

OB: Orange Book Listed Patent

AVMAPKI FAKZYNJA CO-PACK Patent Portfolio

OB: 7,897,792 Avutometinib COM (expiry 2/9/2027)

OB: 11,400,090 – Avutometinib mono dosing - (expiry 10/29/2038) PTE

OB: 7,928,109 Defactinib COM US (expiry 4/17/2028) PTA PTE (Aug, 2034)

OB: 8,247,411 Defactinib – genus (expiry 4/17/2028)

OB: 11,517,573 A+D combo dosing– (expiry 9/11/2040)

OB: 11,873,296 Avuto polymorph – (expiry 12/29/2042)

PTE (May 2039)

GRAPHIC

Filename: tm2613842d1_ex99-1img001.jpg · Sequence: 6

Binary file (86753 bytes)

Download tm2613842d1_ex99-1img001.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img002.jpg · Sequence: 7

Binary file (230996 bytes)

Download tm2613842d1_ex99-1img002.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img003.jpg · Sequence: 8

Binary file (124848 bytes)

Download tm2613842d1_ex99-1img003.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img004.jpg · Sequence: 9

Binary file (119955 bytes)

Download tm2613842d1_ex99-1img004.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img005.jpg · Sequence: 10

Binary file (151052 bytes)

Download tm2613842d1_ex99-1img005.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img006.jpg · Sequence: 11

Binary file (168009 bytes)

Download tm2613842d1_ex99-1img006.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img007.jpg · Sequence: 12

Binary file (137539 bytes)

Download tm2613842d1_ex99-1img007.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img008.jpg · Sequence: 13

Binary file (113514 bytes)

Download tm2613842d1_ex99-1img008.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img009.jpg · Sequence: 14

Binary file (83956 bytes)

Download tm2613842d1_ex99-1img009.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img010.jpg · Sequence: 15

Binary file (175483 bytes)

Download tm2613842d1_ex99-1img010.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img011.jpg · Sequence: 16

Binary file (156017 bytes)

Download tm2613842d1_ex99-1img011.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img012.jpg · Sequence: 17

Binary file (109521 bytes)

Download tm2613842d1_ex99-1img012.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img013.jpg · Sequence: 18

Binary file (102161 bytes)

Download tm2613842d1_ex99-1img013.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img014.jpg · Sequence: 19

Binary file (102997 bytes)

Download tm2613842d1_ex99-1img014.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img015.jpg · Sequence: 20

Binary file (148251 bytes)

Download tm2613842d1_ex99-1img015.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img016.jpg · Sequence: 21

Binary file (159105 bytes)

Download tm2613842d1_ex99-1img016.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img017.jpg · Sequence: 22

Binary file (124036 bytes)

Download tm2613842d1_ex99-1img017.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img018.jpg · Sequence: 23

Binary file (70809 bytes)

Download tm2613842d1_ex99-1img018.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img019.jpg · Sequence: 24

Binary file (152025 bytes)

Download tm2613842d1_ex99-1img019.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img020.jpg · Sequence: 25

Binary file (180524 bytes)

Download tm2613842d1_ex99-1img020.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img021.jpg · Sequence: 26

Binary file (158261 bytes)

Download tm2613842d1_ex99-1img021.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img022.jpg · Sequence: 27

Binary file (184088 bytes)

Download tm2613842d1_ex99-1img022.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img023.jpg · Sequence: 28

Binary file (189465 bytes)

Download tm2613842d1_ex99-1img023.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img024.jpg · Sequence: 29

Binary file (157212 bytes)

Download tm2613842d1_ex99-1img024.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img025.jpg · Sequence: 30

Binary file (108978 bytes)

Download tm2613842d1_ex99-1img025.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img026.jpg · Sequence: 31

Binary file (171946 bytes)

Download tm2613842d1_ex99-1img026.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img027.jpg · Sequence: 32

Binary file (117509 bytes)

Download tm2613842d1_ex99-1img027.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img028.jpg · Sequence: 33

Binary file (105535 bytes)

Download tm2613842d1_ex99-1img028.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img029.jpg · Sequence: 34

Binary file (122307 bytes)

Download tm2613842d1_ex99-1img029.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img030.jpg · Sequence: 35

Binary file (76166 bytes)

Download tm2613842d1_ex99-1img030.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img031.jpg · Sequence: 36

Binary file (105024 bytes)

Download tm2613842d1_ex99-1img031.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img032.jpg · Sequence: 37

Binary file (155372 bytes)

Download tm2613842d1_ex99-1img032.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img033.jpg · Sequence: 38

Binary file (60142 bytes)

Download tm2613842d1_ex99-1img033.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img034.jpg · Sequence: 39

Binary file (107437 bytes)

Download tm2613842d1_ex99-1img034.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img035.jpg · Sequence: 40

Binary file (145505 bytes)

Download tm2613842d1_ex99-1img035.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img036.jpg · Sequence: 41

Binary file (62132 bytes)

Download tm2613842d1_ex99-1img036.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img037.jpg · Sequence: 42

Binary file (127184 bytes)

Download tm2613842d1_ex99-1img037.jpg

GRAPHIC

Filename: tm2613842d1_ex99-1img038.jpg · Sequence: 43

Binary file (84578 bytes)

Download tm2613842d1_ex99-1img038.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 45

v3.26.1

Cover

May 07, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 07, 2026

Entity File Number

001-35403

Entity Registrant Name

Verastem,

Inc.

Entity Central Index Key

0001526119

Entity Tax Identification Number

27-3269467

Entity Incorporation, State or Country Code

Entity Address, Address Line One

117 Kendrick Street

Entity Address, Address Line Two

Suite 500

Entity Address, City or Town

Needham

Entity Address, State or Province

Entity Address, Postal Zip Code

02494

City Area Code

781

Local Phone Number

292-4200

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, $0.0001 par value per share

Trading Symbol

VSTM

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration